Land: Taívan
Tungumál: kínverska
Heimild: 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)
OFLOXACIN
台灣參天製藥股份有限公司 台北市中山區松江路126號9樓之1 (86383884)
S01AE01
點眼液劑
主成分 (OFLOXACIN) ; OFLOXACIN (0836002000) 3MG/ML
塑膠瓶裝
製 劑
須由醫師處方使用
SANTEN PHARMACEUTICAL CO. LTD.(NOTO PLANT) 2-14,SHIKINAMI,HODATSUSHIMIZU-CHO, HAKUI-GUN, ISHIKAWA, JAPAN JP
ofloxacin
外眼部細菌性感染症
註銷理由: 自請註銷; 有效日期: 2026/09/02; 英文品名: OFLOVID OPHTHALMIC SOLUTION
2021-04-14
*Revised: December 2006 (6th version) Standard Commodity Classification No. of Japan 871319 - BROAD-SPECTRUM ANTIBACTERIAL OPHTHALMIC PREPARATION - TARIVID OPHTHALMIC SOLUTION 0.3% < Ofloxacin > DESIGNATED DRUG and PRESCRIPTION-ONLY DRUG CONTRAINDICATIONS (TARIVID OPHTHALMIC SOLUTION IS CONTRAINDICATED IN THE FOLLOWING PATIENTS.) Patients with a history of hypersensitivity to the ingredient of this product or any quinolone antibiotics. DESCRIPTION Brand name Tarivid ophthalmic solution 0.3% Active ingredient Ofloxacin Content per mL 3mg Inactive ingredient Sodium chloride, Dilute hydrochloric acid, Sodium hydroxide, Purified water pH 6.0 − 7.0 Osmolar ratio 0.95 − 1.15 Description Clear, pale to light yellow sterile aqueous ophthalmic solution INDICATIONSSusceptible strains of _Staphylococcus_ sp., _Streptococcus_ sp., _Streptococcus pneumoniae, Enterococcus _ sp. _, Micrococcus_ sp., _Moraxella_ sp., _Corynebacterium_ sp., _ Klebsiella_ sp., _Serratia _ sp., _Proteus_ sp., _Morganella morganii, Providencia_ sp., _Haemophilus _ _influenzae, _ _Haemophilus _ _aegyptius _ [Koch-Weeks bacillus], _Pseudomonas_ sp., _Pseudomonas _ _aeruginosa, _ _Burkholderia _ _cepacia, _ _Stenotrophomonas _ _(Xanthomonas) _ _maltophilia, _ _Acinetobacter_ sp., and _Propionibacterium acnes._ Lestu allt skjaliðBlepharitis, dacryocystitis, hordeolum, conjunctivitis, tarsadenitis, keratitis (including corneal ulcer). DOSAGE AND ADMINISTRATION Usually, instill 1 drop a time 3 times daily. The dosage may be adjusted according to the patient’s symptoms. < PRECAUTIONS > 1. In order to avoid the emergence of resistant bacteria, bacterial susceptibility should be confirmed and treatment with this drug should be limited to the minimum period required for the eradication of the infection. 2. Avoid long-term use. PRECAUTIONS 1. ADVERSE REACTIONS Adverse reactions to this drug were reported in 44 of 13,329 patients evaluated before and after approval (0.33%). The major adverse reactions were eye irritation in 11 patien